Lisata Therapeutics
LSTA
32 hedge funds and large institutions have $9.41M invested in Lisata Therapeutics in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
19% more funds holding
Funds holding: 27 → 32 (+5)
0.16% more ownership
Funds ownership: 0.7% → 0.86% (+0.16%)
6% less call options, than puts
Call options by funds: $1.06M | Put options by funds: $1.13M
7% less capital invested
Capital invested by funds: $10.1M → $9.41M (-$691K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.25M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$313K |
| 3 |
Renaissance Technologies
New York
|
+$241K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$97K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$35.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$104K |
| 2 |
Goldman Sachs
New York
|
-$87K |
| 3 |
Morgan Stanley
New York
|
-$18.1K |
| 4 |
GPFA
Game Plan Financial Advisors
Westlake,
Ohio
|
-$10.5K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.76K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KFS
26
Kelly Financial Services
Braintree,
Massachusetts
| $12 | – | – | – |
|
|
RE
27
RBC Europe
London,
United Kingdom
| $12 | – | – | – |
|
|
28
Millennium Management
New York
| – | -$104K | -4,327 | Closed |
|
|
29
Goldman Sachs
New York
| – | -$87K | -3,592 | Closed |
|
30
Bank of America
Charlotte,
North Carolina
| – | -$608 | -31 | -37% |
|
31
Wells Fargo
San Francisco,
California
| – | +$78 | +4 | +19% |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| – | +$196 | +10 | New |
|
LSTA Hedge Fund Activity: Q3 2021 in Review
32 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q3 2021, worth a combined $9.41M — down 6.8% from $10.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new LSTA positions and 2 closed out — a net gain of 5 holders — while 9 added to existing stakes and 5 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.25M. The largest seller was Millennium Management, exiting entirely with an estimated $104K sold.
- 32 institutional investors held Lisata Therapeutics (LSTA) as of Q3 2021, up from 27 in Q2 2021.
- Funds reported $9.41M of Lisata Therapeutics stock for Q3 2021, down 6.8% quarter-over-quarter.
- 7 funds opened new Lisata Therapeutics positions in Q3 2021 and 2 closed out, a net change of +5 holders.
- The largest Lisata Therapeutics buyer in Q3 2021 was Sabby Management, an estimated $1.25M added.
- The largest Lisata Therapeutics seller in Q3 2021 was Millennium Management, an estimated $104K sold.
Based on aggregated 13F filings for Q3 2021.